Want to see HK:1276 full AI Analyst Report?
1276 Stock Chart & Stats
HK$46.50
HK$0.40(0.71%)
At close: 4:00 PM EDT
HK$46.50
HK$0.40(0.71%)
Day’s Range― - ―
52-Week RangeHK$45.66 - HK$95.20
Previous CloseN/A
Volume2.78M
Average Volume (3M)3.62M
Market Cap
HK$362.33B
Enterprise ValueHK$338.39K
Total Cash (Recent Filing)HK$44.89B
Total Debt (Recent Filing)HK$836.30M
Price to Earnings (P/E)39.0
Beta0.55
Next Earnings
Oct 23, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend Yield0.5%
Share Statistics
EPS (TTM)1.32
Shares Outstanding258,197,600
10 Day Avg. Volume2,417,952
30 Day Avg. Volume3,618,442
Financial Highlights & Ratios
PEG Ratio2.21
Price to Book (P/B)6.79
Price to Sales (P/S)13.15
P/FCF Ratio50.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$82.13Price Target Upside76.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)1.61
Revenue Forecast (FY)HK$39.43B
Bulls Say, Bears Say
Bulls Say
Very High ProfitabilityExceptional gross and net margins provide a durable earnings base and indicate strong product economics. Sustaining these margins can support internal funding for pharmaceutical research, regulatory work, manufacturing capacity, and commercial expansion.
Exceptionally Conservative Balance SheetMinimal debt gives the company substantial financial flexibility through clinical development cycles and market changes. Low interest and solvency risk also leave more capacity to fund innovation, pursue partnerships, and absorb potential product setbacks.
Strong Operating Cash Flow QualityOperating cash flow exceeding reported earnings suggests that profitability is supported by cash generation rather than relying primarily on accounting gains. This strengthens the company’s ability to reinvest in its drug pipeline and sustain operations.
Bears Say
Recent Top-line SoftnessA decline in trailing revenue indicates that current commercial momentum is weaker despite strong margins. Persistent top-line softness could limit operating leverage, reduce funding for research, and increase dependence on successful launches or portfolio renewal.
Free Cash Flow DeteriorationLower and more volatile free cash flow suggests greater reinvestment or working-capital demands are absorbing earnings. If this persists, internally generated funds available for clinical programs, acquisitions, dividends, or debt-free expansion may be constrained.
Returns Are Not AcceleratingStable but unaccelerating returns indicate that the company’s high margins and low leverage have not yet translated into stronger capital efficiency. This may signal limits to near-term value creation unless growth, product mix, or asset utilization improves.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H News
1276 FAQ
What was Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price range in the past 12 months?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H lowest stock price was HK$45.66 and its highest was HK$95.20 in the past 12 months.
What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s market cap?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s market cap is HK$362.33B.
When is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date is Oct 23, 2026 which is in 52 days.
How were Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s earnings last quarter?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H released its earnings results on Aug 19, 2026. The company reported HK$0.394 earnings per share for the quarter, missing the consensus estimate of HK$0.483 by -HK$0.089.
Is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H overvalued?
According to Wall Street analysts Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price is currently Undervalued.
Does Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H pay dividends?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H pays a Notavailable dividend of HK$0.228 which represents an annual dividend yield of 0.5%. See more information on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H dividends here
What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s EPS estimate?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s EPS estimate is 0.4.
How many shares outstanding does Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H have?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has 258,197,600 shares outstanding.
What happened to Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price movement after its last earnings report?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H reported an EPS of HK$0.394 in its last earnings report, missing expectations of HK$0.483. Following the earnings report the stock price went up 1.29%.
Which hedge fund is a major shareholder of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:1276
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
0.50%
Trailing 12-Months
Asset Growth
18.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Earnings & Revenues
1276 Stock 12 Month Forecast
Average Price Target
HK$82.13
▲(76.62% Upside)
Technical Analysis
Sino Biopharmaceutical
―
Innovent Biologics
―
Akeso, Inc.
―
Hansoh Pharmaceutical Group Company Limited
―
BeOne Medicines Ltd
―